17 jul: BASE METALS HIGHLIGHTS: Top Stories of the Day
17 jul: UPDATE: CSX 2nd-Quarter Profit Up 1.2% as Intermodal, Automotive ..
17-07-2012 23:37:00

GlaxoSmithKline and Amicus Expand Drug Collaboration

Relateret indhold

By Ben Fox Rubin

Amicus Therapeutics Inc. (FOLD) and GlaxoSmithKline PLC (GSK, GSK.LN) said they are expanding their collaboration to develop a treatment for Fabry disease, with Glaxo agreeing to buy a larger stake in the smaller pharmaceutical company.

The deal includes co-development of all current and future formulations of migalastat HCl for Fabry disease, which is a lipid storage disorder, as well as a commercialization arrangement for all future Fabry products. Amicus will have commercial rights in the U.S., while Glaxo will have rights for the rest of the world.

Glaxo also agreed to buy $18.6 million in Amicus's common stock at $6.30 a share, a 4.7% premium over Tuesday's close, raising its ownership in the company to 20%.

"Through our expanded agreement, GSK is increasing its investment in the Fabry development program and Amicus is transforming into a commercial-stage biopharmaceutical company within the U.S.," said Amicus Chief Executive John Crowley.

Amicus makes oral therapeutics known as pharmacological chaperones to treat a range of human genetic diseases.

Its shares closed Tuesday at $6.02, while Glaxo's closed at $45.44. Neither were active after hours.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

July 17, 2012 17:37 ET (21:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Spar Nord kan blive presset til blokade i Nørresundby-salg

28-01-2015 16:04:45
Spar Nord kan fortsat ende med at stille sig i vejen for Nordjyske Banks køb af Nørresundby Bank, selv om Spar Nord tidligere i januar trak sig fra budkrigen.Be..

Nordea-topchef vil ikke udelukke negative renter

28-01-2015 12:37:17
Et scenarie, hvor kunderne skal betale for at have penge stående i banken, ar måske utænkeligt for få år siden. Men ideen om negative indlånsrenter mødes ikke l..

Aktier/middag: Regnskaber sender Nordea og Tryg til tops

28-01-2015 11:39:25
Finanssektoren sætter et stort fingeraftryk på det danske aktiemarked onsdag. Nydelige regnskaber fra Nordea og Tryg belønnes med store kursstigninger i et mark..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Torm nærmer sig ny redningskrans med betingelser - NY
2
Nordea Q4: Øger overskud og udbytte
3
Apple overgik enhver forventning i seneste kvartal
4
Tryg slår markedets forventninger med flere længder
5
Tre finansselskaber løfter aktierne

Relaterede aktiekurser

GlaxoSmithKline PLC 44,99 -0,4% Fald i aktiekurs
Amicus Therapeutics Inc 7,83 -3,8% Fald i aktiekurs
GlaxoSmithKline PLC 1.485,77 0,0% Aktiekurs uændret

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. januar 2015 05:18:19
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150128.1 - EUROWEB2 - 2015-01-29 05:18:19 - 2015-01-29 05:18:19 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x